{
    "2019-10-30": [
        [
            {
                "time": "",
                "original_text": "养老目标基金总规模200亿最高赚15% 怎么投资的？",
                "features": {
                    "keywords": [
                        "养老目标基金",
                        "规模",
                        "投资"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "从仿制走向创新，恒瑞、豪森等的创新路径有何差异？",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "豪森",
                        "创新路径"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "",
                "original_text": "艾迪药业IPO：管理费高企研发不足 供应商竟有个体户",
                "features": {
                    "keywords": [
                        "艾迪药业",
                        "IPO",
                        "管理费",
                        "研发不足"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药(600276.SH)：国家药监局已受理氟唑帕利胶囊的药品注册申请",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "药监局",
                        "氟唑帕利胶囊",
                        "药品注册申请"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "基金三季报持仓报告，透露了哪些配置信息？",
                "features": {
                    "keywords": [
                        "基金",
                        "三季报",
                        "持仓报告",
                        "配置信息"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "突破4000亿市值后 恒瑞又一重磅新药获批！本土药企VS老牌MNC",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "市值",
                        "重磅新药",
                        "获批",
                        "本土药企",
                        "MNC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[国盛证券张金洋团队]恒瑞医药：两大品种申报上市，在研管线超预期推进",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "品种申报",
                        "在研管线",
                        "推进"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物单抗行业深度系列：靶点篇，马千里",
                "features": {
                    "keywords": [
                        "医药生物",
                        "单抗",
                        "靶点",
                        "行业深度"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "",
                "original_text": "融资余额6连升 猪周期概念股获增持逾11亿元",
                "features": {
                    "keywords": [
                        "融资余额",
                        "猪周期",
                        "概念股",
                        "增持"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "农业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[医药]公募基金三季报发布，医药继续处于超配状态——医药行业周报——中性（联系人：徐勇、甘英健、陈晨、张山峰）",
                "features": {
                    "keywords": [
                        "公募基金",
                        "三季报",
                        "医药",
                        "超配状态"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}